CD19 and systemic lupus erythematosus: Early clinical data from CD19-directed CAR-T therapy in refractory SLE demonstrate the potential to induce remission accompanied by profound depletion of CD19+ naïve and memory B-cell compartments, followed by repopulation with predominantly CD21+CD27- naïve B cells during reconstitution.